Seattle Genetics is cancer drug company that is located in Bothell, Washington, just outside of Seattle. This company was founded in 1998 and CEO Clay Siegall was one of the original founders. Also serving as Chairman of the Board, Clay holds multiple degrees. He earned his B.S. in Zoology from the University of Maryland and he earned his Ph.D. in Genetics from George Washington University. He has also written over 70 publications and he currently holds 15 patents. All of this is just a small portion of what helps Clay Siegall lead Seattle Genetics.
In recent years, Seattle Genetics has been working on some big plans. These plans cover multiple areas of the company and they are very ambitious. Currently, Adcetris is the lead drug that Seattle Genetics is researching, developing and marketing. This drug is used to treat Hodgkin lymphomas. It is being sold all over the world and has led to big profits for the company. They now want to expand on that.
Seattle Genetics is currently working on adding 12 more drugs to their lineup. These drugs will cover many types of cancers and their reach will be great. To help with all that goes into creating these drugs, more employees will be needed. Seattle Genetics is looking to add 100 employees in the near future. These 100 will be located in the United States based offices. In addition, another 20 employees will be added to the Switzerland-based office. All of the new employees will be on the operations side of the company.
Currently, Seattle Genetics has over 800 employees. Adding more employees and adding more cancer treating drugs to the company means big things are yet to come. The fight to find cancer treatments and cures continues and Seattle Genetics wants to play a larger role in that fight.